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Advancements in sequencing in the past decades enabled not only the determination of the human proteome but
also the identification of a large number of genetic variations in the human population. The phenotypic effects of
these mutations range from neutral for polymorphisms to severe for some somatic mutations. Disease-causing
germline mutations (DCMs) represent a special and largely understudied class with relatively weak phenotypes.
While for somatic mutations their effect on protein structure and regulation has been extensively studied in select
cases, for germline mutations, this information is currently largely missing. In this analysis, a large amount of
DCMs were analyzed and contrasted to polymorphisms from a structural point of view. Our results delineate the
characteristic features of DCMs starting at the global level of partitioning proteins into globular, disordered and
transmembrane classes, moving toward smaller structural units describing secondary structure elements and
molecular surfaces, reaching down to the smallest structural entity, post-translational modifications. We show
how these structural entities influence the emergence and possible phenotypic effects of DCMs.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Mutations can impact proteins on several levels,
perturbing structural stability, affecting folding, modu-
lating degradation, and can lead to improper trafficking,
or the emergence of toxic conformations [1]. The
theoretical spectrum of genetic variations ranges from
neutral to lethal through increasingly strong pheno-
types. Neutral or near-neutral polymorphisms (PMs)
are present in a large portion of the human population
without any obvious loss of fitness. However, the
majority of non-lethal mutations is expected to cause a
noticeable phenotypic effect and thus is under signif-
icant negative selection. Many of these are disease-
associated or disease-causing mutations (DCMs) that
form the genetic background of a wide range of
pathological conditions. Personalized medicine is a
rapidly growing area based on the idea that individual's
genetic content can be used to offer a more precise
treatment. The early recognition of harmful changesnotthors. Published by Elsevier Ltd. This is a
g/licenses/by-nc-nd/4.0/).only helps a more personalized medication but also
increases the chance it is delivered prior to irreversible
changes.
The identification of a germline mutation cannot
usually be done from a single sequencing step
without a reference independent of the patient, and
the study of familial background is often a must. As a
result, early studies considering the phenotypic
effects of germline DCMs were restricted to a few
proteins only [2,3], and systematic analyses were
not possible due to the lack of known variations and
structures. In recent years, the number of solved
protein structures has grown exponentially, and the
amount of available germline DCM data is also
constantly increasing, making systematic analyses
of DCMs and PMs in proper structural background
available The growing number of all-atom structures
also helps the development of different prediction
methods, helping analyses to be extended to
proteins without a solved structure.n open access article under the CC BY-NC-ND license
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4956 Disease-Causing Germline MutationsOne way to describe protein structure is through
geometric properties. There are several papers em-
phasize the importance of surfaces, such as protein–
protein interaction (PPI) and buried parts, both large-
scale [4–7] and individual studies [8]. Analysis of
physico-chemical features adds an additional layer to
this information: DCMs often destabilize the structure
by disrupting hydrophobic, polar interactions and
disulfide and salt bridges [9]. On the other hand, over-
stabilization can be also disease causing if the required
level of flexibility tomaintain a function is damaged [10].
Someof these studiesalso consider bindingaffinity [11]
or analyzed their effect on enzymatic function [12].
These publications mutually agree that disruption of
compact structural entities of rewiring PPI networks
carry a lot of disease. Another approach is the
consideration of the (lack of) periodic structure ele-
ments and domains: several papers investigate the
effect of protein disorder. Due to the problematic
experimental capture of flexibility, these investigations
are usually based on prediction methods, and they
conclude thatDCMsare depleted in disordered regions
and suggest that such variations often stabilize the
structure [13–15]. Around 25% of the human proteome
is transmembrane protein (TMP): our previous study
suggested that non-polar to non-polar amino acid
changes and non-polar to charged ones are equally
frequent in TMPs carrying DCMs and that mutations to
positively charged amino acids in the central of the lipid
bilayer often cause disease [16]. Finally, post-
translational modifications (PTMs) are the smallest
structural/functional units of proteins and DCMs accu-
mulate around these sites compared to expected
[5,17].
Although these papers offer prospect to DCMs, to
better understand how single-nucleotide polymor-
phisms perturb function, a more complex point of
view is necessary, considering several structural
features at the same time rather than individually.
DCMs in TMPs, disordered proteins and globular
proteins were studied in details individually; however,
the presence of DCMs compared between these
structural groups was not considered so far. How
DCMs are spread in these classes? Do mutational
preferences for individual diseases provide a struc-
ture-based classification? Protein interactions can be
classified based on the interplay between folding and
binding [18]. How does such grouping influence our
current knowledge regarding the occurrences of
DCMs on different surfaces? Predicting topology of
TMPs is one of the most reliable parts of structure-
based predictions, yet topology-based analysis of
TMPs and DCMs is completely missing. Is there any
connection between the occurrence of DCMs and
biophysical laws aiding the folding of TMPs? How
PTMs behave on different surfaces? Phosphomi-
metics is a common event in cancer. Do germline
DCMs also exploit this phenomenon? It is common
knowledge that DCMs are rare in disordered regionscompared to ordered domain, yet do we see
exceptions by utilizing a more complex point of view?
Since the known structural space is constantly
growing and new variations are also often deposited
into dedicated databases, it is also useful to revisit
the topic time to time. Somatic and germline
mutations affect protein function and cell survival in
different ways. Is this reflected on the structure level
of proteins? In the present study, we try to answer
these questions using statistical methods as well as
by investigation of specific examples.Results
DCMs preferentially target structured protein
regions
Togain ageneral insight into the connection between
various types of mutations and structural regions of
proteins, all residues in the human proteome were
classified into three distinct structural groups: trans-
membrane (TM), ordered, and disordered; the occur-
rencesofPMsandDCMs ineachclasswere compared
to that expected from random. As expected from their
neutral nature, the occurrences of PMs (even if they
deviate from the random background) are close to
expected values in all structural parts (Fig. 1A, blue
triangle). In contrast, DCMs are significantly accumu-
lated on TM and ordered protein regions. This
observation is also confirmed by considering domains
defined inPfam,whereDCMsare significantly enriched
(Supplementary Fig. 1). In contrast, DCMs are less
frequent in disordered protein regions, in line with the
higher mutation tolerance of protein regions without
stable structures [19] (Fig. 1A, red triangle).
While the definitions of ordered and TM protein
regions are straightforward (the presenceof a structure
in aqueous solution or in a lipid bilayer was confirmed
for at least in a homolog in all studied cases), the above
definition of disordered sequence parts is largely
based on prediction. While this enables the analysis
on the whole human proteome, the results in theory
could depend on the choice of algorithm. In order to
eliminate this potential bias [20], we further analyzed
disordered residues in three independent ways,
employing three different definitions for disordered
residues. The first two definitions rely on experimental
validation, considering residues with missing coordi-
nates in X-ray PDB structures, or using data from the
DisProt database. These two approaches cover two
different “flavors” of disorder [21], with the former
describing short disordered linkers, loops and terminal
regions, while the latter better represents long disor-
dered regions. In a third,more permissive approach, all
protein regions falling out of well-characterized struc-
tural parts were considered. These regions are also
expected to contain a high number of intrinsically
Fig. 1. The space of human protein sequences. A, Enrichments of PMs andDCMs in TM, ordered and disordered residues.
p-Values are b0.01 in all cases, where the expected number of PMs and DCMs in a certain structural parts was tested (χ2 test,
see Supplementary Material for exact values). B, Distance distributions between PMs and DCMs (top, sequence analysis;
bottom, structure analysis). p-Values are b0.01 in all cases (two-sample Kolmogorov–Smirnov test; blue, PMs; red, DCMs).
4957Disease-Causing Germline Mutationsdisordered regions/proteins (IDR/IDP), albeit also
containing other, possibly structured segments.
Using any of the above alternative definitions, the
depletion of DCMs in disordered residues is significant
(Supplementary Fig. 2).
Proteins are generally modular, and most human
proteins contain several structural/functional units (e.g.,
domains, linkers, TM regions, etc.). The presence of
distinct modules is expected to perturb the distribution
of the location of mutations with functional importance.
In order to test this assumption, we investigated the
average distance of various PMs along the protein
sequence and contrasted this distribution with that
calculated for DCMs. The residual distances of PMs
seem to be evenly distributed, in contrast to DCMs,
where shorter distances between mutations are more
common. (Fig. 1B, top) This suggests that DCMsprefer
to cluster close to each other, potentially targeting
selected protein modules. This observation is even
more pronounced when the spatial distribution of
mutations calculated from PDB structures is taken
into consideration, showingapeakofDCMdistancesat
12 Å (Fig. 1B, bottom). This observation hints that
certain parts of the protein are more vulnerable to
alterations and DCMs tend to specifically target them.
In the next sections, we investigate the resilience of
specific structural/functional regions to various types of
mutations, and how DCMs and PMs perturb various
structural units.Structural features of mutations offer a natural
classification of diseases
Most analyzed hereditary diseases are monogenic
with all annotated mutations affecting the same protein
(2460 out of 2540 diseases—obtained from humsavar,
filtered by MIM identifier). However, as the affected
proteins can be highly modular including ordered,
disordered and TM regions, mutations from a single
disease can—in theory—affect more than one type of
structural region. While illnesses can be classified
according to a wide range of criteria (chromosomal
location, severity, inheritance type, etc.), the potential
interplay between various types of protein structural
regions in the emergence of the phenotype provides a
novel, molecular basis for grouping various diseases.
In order to test the validity of a molecular structure-
based classification approach, each disease in our
data set was represented by a three-element vector
that encodes the fraction of associated mutations in
ordered, disordered and TM regions. These vectors
were used as input to a hierarchical clustering
algorithm. The resulting tree depicting linkage of
various diseases is shown in Fig. 2A. Apart from
hierarchical clustering, k-means clustering was also
used, to reveal the optimal number of clusters to
partition the data. Inspecting the within-cluster sum of
squares as a function of the number of clusters, the
most pronounced elbow corresponds to partitioning
Fig. 2. The structural definition of the three types of diseases. A, the tree resulting from hierarchical clustering of
diseases based on structural content (left) and the k-means evaluation of various numbers of clusters. B, The average
fraction of mutations falling into the three types of structural regions for diseases in the three classes (top); the fraction of
mutations linked to autosomal, X, Y chromosomes, respectively, or the mitochondrial DNA (bottom). Bold values mark
higher ratio of diseases (see text for details). C, Examples for the three types of diseases. Positions with known disease-
associated germline mutations are marked in red. For MeCp2, regions in gold mark flexible/unstructured regions based on
NMR structure (PDB ID: 1qk9). MFSD8 was modeled by Swissmodel [22], and the membrane plane was defined by
TMDET [23].
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4959Disease-Causing Germline Mutationsthe data into three clusters. In accord, we considered
three types of diseases; however, as the k-means
analysis shows, further potentially relevant sub-
classes can be identified by increasing the numbers
of final clusters (Fig. 2A).
The three structural composition-based types of
diseases show marked differences (Fig. 2B). Type I
contains diseases that arise predominantly via ordered
mutations. This group is dominated by autosomal
mutations but also contains all known hereditary
diseases that are linked to Y-chromosomal inheri-
tance. A prototype of this class isGaucher disease that
is caused by mutations in the glucosylceramidase
enzyme disrupting lysosomal storage. Glucosylcera-
midase is a single domain ordered enzyme with a
monomeric active form. This domain can be destabi-
lized via a large number of point mutations, most of
which (105 out of 113) are buried in the hydrophobic
core (Fig. 2C). This destabilization reduces enzyme
activity, and the occurring mutations determine the
severity and onset age of the disease. This destabiliz-
ing effect can be countered by the use of small
molecules that can increase domain stability [24].
The second group of diseases exhibit markedly
different structural composition. While in this class the
majority of mutations also fall into ordered protein
regions, there is a significant portion of variations that
affect disordered regions as well. This shows that the
coordination between order and disorder in disease
emergence is a common theme for a wide range of
illnesses. Interestingly, this class shows a higher ratio
of X-chromosome-linked disease showing a non-trivial
connection between preferred protein structural re-
gions and inheritance type. A typical example for these
type II illnesses is the X-linked RETT syndrome. This
disease is linked to the mutations of the MeCp2
protein, which is a generic transcriptional repressor
binding to methylated DNA. The majority of observed
mutations (28 out of 46) can be mapped onto the DNA
binding domain and disrupt or weaken the DNA
binding leading to epigenetic deregulation. While the
DNAbinding domain has a stable structure in isolation,
it contains three discernable disordered/highly flexible
regions encompassing the two termini and a middle
region between residues 110–120 [25]. The known
mutations can bemapped to both the highly structured
and the flexible regions, indicating the coordination
between the two structural units. Furthermore, the rest
of the protein is predicted to be largely unstructured
and the rest of the observed germline mutations affect
these regions emphasizing the importance of interplay
between protein order and disorder.
The third class of diseasesmarks the realm of TMPs.
While ordered mutations still represent a large factor,
on average, over half of the mutations linked to
diseases of third class affect TM regions. In accord,
this class encompasses the vast majority of mitochon-
drial diseases. A prime example of such disease is
ceroid lipofuscinosis that is linked to mutations in theMfsd8 protein, a lysosomal TMP that is capable of
transporting small solutes using chemical gradients.
Mfsd8 contains 12 TM regions, half of which carry
disease-linkedmutations. In addition, three intracellular
and one extracellular short helix-connecting loops are
also mutated. Half of these mutations cause a change
in charge, which can easily modulate the protein's
interaction with the surrounding ionic environment.
However, the other half of mutations typically affects
hydrophobic residues, indicating that the interaction
between various TM regions can also be modulated.
Diseases belonging to the three classes of
structurally defined groups exhibit different charac-
teristics at the molecular level. While the above
examples provide insights into these mechanisms, it
is an open question how structure and function are
modulated in general via the three classes of
structural elements. In the following chapters, we
aim to provide an assessment for possible points of
modulation in TM, disordered and ordered proteins.
DCMs and the positive-inside rule of TMPs
As TM regions show a strikingly high enrichment in
DCMs compared to neutral mutations, the exact
location of DCMs in these proteins was analyzed in
greater detail. TMPs were partitioned into distinct
structural segments: TM and terminal regions, mem-
brane proximal segments, and connecting loops.While
the distribution of PMs on all regions was very close to
random (see Fig. 3), DCM distributions show targeted
enrichment in several region classes. The distribution
of DCMs in TM regions of bitopic and polytopic proteins
was separately investigated (Fig. 3). Single spanning
TM regions are depleted in DCMs, in contrast to TM
regions of polytopic proteins. As helix formation is
driven by hydrogen bonding between mainchain
atoms, single α-helical structures are difficult to disrupt
by a change in side chains caused byDCMs.However,
in the case of polytopic TM segments, the helix–helix
interactions serve as much more accessible targets for
structural disruption, as these interactions are typically
mediated through sidechain–sidechain interactions.
Apart from polytopic TM regions, a distinct enrichment
ofDCMscanbeobserved in cytosolic connecting loops
(i.e., a five-residue extension from membrane bound-
ary on the cytosolic side).
We further analyzed these cytosolic regions and
looked for loops containing positively charged residues
that are known to govern the orientation of TMPs in the
membrane according to the positive-inside rule [26].
DCMs in these regions are enriched compared to other
parts of TMPs. To rule out every other scenario, we
have compared the accumulation of DCMs in cytosolic
extensions with and without charged residues, as well
as extra-cytosolic extensions. The enrichment values
calculated separately for these regions show (Fig. 3)
that the main enrichment effect can be traced to the
presence of inside positive residues.
Fig. 3. A, Enrichments of variations on different parts of TMPs. 1TMmarks single pass TMPs, andMTMmarks polytopic
TMPs. ** and * mark significant p-values (b0.01 and b0.05, respectively) according to χ2 test on the observed values
(blue, PMs; red, DCMs).
4960 Disease-Causing Germline MutationsIn addition to the positive-inside rule, it was reported
that there is a negative-inside depletion/outside
enrichment rule [27]. Therefore, we performed an
analysis on outsidemembrane proximal residues.We
discriminated regions containing negatively charged
residues (D, E). According to this analysis, DCMs are
accumulated in membrane proximal extra-cytosolic
regions, although negatively charged residues occur
in these regions (Supplementary Table). Although a
slight increasement is presented in regions containing
D, E residues, this result is not significant according to
χ2 test (Supplementary Table).
In contrast, DCMs are depleted in terminal regions,
both in polytopic and bitopic proteins (Fig. 3).
According to GO overrepresentation analysis,
genes mutated near the membrane were exclusively
enriched in proteins related to various transport
functions, while GO term for genes carrying DCMs in
terminal regions included signaling processes as
well, for example, “sensory perception of pain” or
“localization” (see Supplementary Table).
DCMs in protein–protein interfaces are influenced
by how folding occurs
In order to assess how various mutations affect
ordered, globular structures and PPIs mediated bythem, mutations falling into oligomeric protein complex
structures from the PDB were examined (Supplemen-
tary Fig. 3). DCMs are enriched on buried residues and
protein–protein interfaces; however, exposed residues
are depleted in them. In contrast, PMs show a reverse
trend being enriched on exposed residues and
depleted on buried residues. The difference between
DCMs and PMs on buried residues shows that the
structural integrity of a foldedprotein canbemoreeasily
disrupted via their core, and hence, these regions are
generally less tolerant to variations. A very similar trend
is true in the case of residues belonging to interaction
interfaces: in these cases, the individual protein
structures stay intact, but the complex formation can
be often blocked or the interaction strength can be
significantly shifted via single-residue changes.
The distribution of DCMs seems selective not only
for the spatial location of the residues but also on the
secondary structure they belong to. Analyzing protein
structures using DSSP for secondary structure
assignation and examining the location of variations
show that extended residues are enriched in DCMs
(especially when mutated to Proline), while irregular
residues are depleted in them (Supplementary Fig. 4).
Surface (Supplementary Fig. 5) and secondary
structure analyses (Supplementary Fig. 6) were
performed on single-subunit proteins as well, and the
4961Disease-Causing Germline Mutationsresults confirm observations made on the oligomer
structure set.
While all studied protein complexes have a stable
structure, there can be significant differences between
individual constituent proteins regarding their mono-
meric structures. It has been shown that while many
IDPs adopt a stable conformation upon interacting with
protein partners, their inherent flexibility in their
unbound form has a serious impact on the resulting
complex and its biophysical properties. We aimed to
gain an insight into how the monomeric structural
properties of proteins forming interactions reflect in how
various mutations target their residues. Regarding the
unbound structure of interacting proteins, we distin-
guish three basic types of protein complexes: autono-
mous folding and independent binding (i.e., the binding
of two or more ordered proteins), coupled folding and
binding (where one ormore orderedproteins serve as a
template to stabilize an IDP partner) and mutual
synergistic folding (interactions formed exclusively by
IDPs). As known PPIs are dominated by ordered
proteins, complexes involving IDPs are scarce in
comparison. As a result, the amount of data is very
low in some cases; however, several interesting trends
can be noticed. DCMs are somewhat enriched on
ordered–ordered PPIs; however, this accumulation is
not significant, in contrast to complex interfaces where
one of the partners is disordered. Moreover, the
enrichment of DCMs is even higher for complexes
where all partners are disordered (Fig. 4). This trend is
unexpected, since DCMs are depleted in disordered
residues in general; however, it suggests that disorder
to order transitions are prime targets for disease-
associated variations. As IDPs undergoing coupled
folding and binding almost always donate all their
residues into the interaction, these IDPs have virtually
no buried residues in their complexed forms. As a
result, this category cannot be studied separately.
While for IDPs undergoingmutual synergistic folding, a
restricted fraction of residues can get buried without
being in direct contact with the partner, these residues
do not harbor any known DCMs, as are also exempt
from further analyses. It is also notable, however, that
the data set of complexes exclusively formed by
ordered proteins contains dimers only. According to
Supplementary Fig. 3, DCMs are enriched on PPIs,
when all structures are considered, regardless the
number of participating proteins chains. Two proteins
were manually discarded from this analysis: transthyr-
etin and superoxide dismutase (UniProt AC: P02766
and P00441, respectively), as they contain extremely
high numbers of DCMs that would bias observations.
Both proteins represent specialized cases for disease
development, having high tendencies to aggregate and
form fibrils. These proteins and their corresponding
illnesses (familial amyloid polyneuropathy and amyo-
trophic lateral sclerosis) are heavily studied concerning
the structural and functional consequences of
mutations.Stabilizing mutations on exposed residues are
harmful when they are in the proximity of
protein–protein interfaces
The contribution of a mutation to the stability of a
protein or a protein complex can be approximated by
the free energy change calculated from introducing
the mutation into known structures using FoldX. The
calculated ΔΔG energy changes can be categorized
as highly stabilizing (b−1.84 kcal/mol), stabilizing
(−1.84 to −0.92 kcal/mol), slightly stabilizing (−0.92
to −0.46 kcal/mol), neutral (−0.46 to +0.46 kcal/mol),
slightly destabilizing (+0.46 to +0.92 kcal/mol), desta-
bilizing (+0.92 to +1.84 kcal/mol) and highly destabi-
lizing (N +1.84 kcal/mol) [28]. In general, PMs perturb
the overall stability to a much lower extent compared
to DCMs (Supplementary Fig. 3). This shows that the
primary effect of DCMs is the disruption of protein
structure by the disruption of PPIs via sterical effects.
This idea is supported by the less emphasized
difference between ΔΔG values of DCMs and PMs
that occur on exposed residues (Fig. 4). Although
extreme values slightly shift these averages, PMs are
in general neutral on PPIs and exposed residues, and
slightly destabilizing on buried residues. In contrast,
DCMs are highly destabilizing on PPIs and buried
residues, however—similarly to PMs—when they
occur on exposed surfaces, their destabilizing effect
is much lower (Supplementary Fig. 3). There are
several individual cases, when the energy change is
negative, yet the variation is harmful. This means that
protein structure is not disrupted and the impaired
function is caused by other event (e.g., on PPIs, this
can be explained that the overall contribution pro-
motes a more compact structure; however, the steric
changes prevent the highly specific binding. Another
plausible scenario is that interactions required to be
dynamic with partners are able to come apart;
however, the mutation prevents the dissociation).
Over-stabilization can also change catalytic activity or
promote aggregation. Considering the three types of
complex formation, the same general observations
can bemade. However, when only one of the partners
is disordered, apparently DCMs cause a slightly
negative (nearly zero) energy change (on average)
on exposed residues.
Disease-associated mutations modulate PTMs
at multiple levels
PTMs are regulatorymechanisms that influence the
function, localization or the interactions of a protein.
Given their importance and their extremely localized
nature (being composed of a single residue), PTMs
are prime candidate targets for disease-associated
mutations, and their alterations are expected to have
serious effects. As the most widely occurring PTM is
Ser/Thr/Tyr phosphorylation, our analysis of the co-
occurrences ofPTMsandDCMs/PMswas focused on
Fig. 4. Variations on protein complex surfaces separated by how folding and binding occurs. Upper rows: Enrichments
of variations on different surfaces. ** and * marks significant p-value (b0.01 and b0.05, respectively). Lower rows: part of
energy change distributions on different surfaces. Vertical black line: interquartile range, horizontal black line: median,
horizontal green line: average. The grids help to identify (de)stabilizing ranges. “X” marks surface parts without sufficient
number of variations for analysis (blue, PMs; red, DCMs).
4962 Disease-Causing Germline Mutationsphosphosites not considering other types of PTMs,
such as methylation or acetylation.
Phosphorylation attaches a phosphate group on
one of the three residues Ser, Thr or Tyr. The most
fundamental biophysical effect of these modifica-
tions is the introduction of a negative charge on an
otherwise neutral residue. Phosphorylation events
often function as a switch between the non-modified
(OFF) state and the modified, charged (ON) state.
Mutations affecting phosphosites can rewire these
switches in two different ways, with changes to Asp
or Glu permanently mimicking the negative charge
contribution of the phosphorylation (forced ON
state), or changes to any other positively charged
or neutral amino acids that abolish the phosphory-
lation event (forced OFF state).Table 1 shows the enrichment of DCMs and PMs in
phosphorylation sites in disordered regions, and
exposed and interface residues of protein complexes.
Strikingly, mutations that lead to a forced ON state are
virtually non-existent among either DCMs or PMs.
While there are two cases where a DCM leads to
the induction of a negative charge, both cases entail a
Tyr → Asp change. While Asp or Glu can functionally
replace a phosphorylated Ser of Thr, both naturally
occurringnegatively chargedaminoacids aregenerally
very poor phosphomimetics for Tyr. In contrast, a
forcedOFF state is achieved in several known cases of
phosphosites. The overlap between phosphosites and
DCMs/PMs does not differ to a large extent when
considering disordered regions. However, in protein
complexes, DCMs seem to preferentially target
Table 1. Relative frequencies of mutations occurring on phosphorylation sites in various structural parts (‰).
Ordered protein–protein complexes Disordered protein
regions
Exposed PTMs Interface PTMs
PMs DCMs PMs DCMs PMs DCMs
Direct modulation (mutated phosphosite)
Forced ON state 0 4 0 0 0 0
Forced OFF state 8 20 14 40 3 1
4963Disease-Causing Germline Mutationsinterface residues when compared to PMs. This
preference is easy to explain, as the abolishment of a
phosphorylation event can directly modulate the
interaction. Interestingly, the difference between PM
andDCMenrichment in phosphosites is even larger for
exposed residues, outside of direct contact with the
partner in the complex structures. These exposed sites
might mark recognition sites for other molecular factors
absent from the studied complexes. However, the
significant enrichment of DCMs underlines the func-
tional importance of these sites with largely unknown
functional relevance. This possibly indicates that while
the available protein complex structures might give a
fair representation of interactions from a structural
standpoint, however, a large fraction of functional
interactions are currently not represented in the PDB
at structural detail.
Apart from the direct mutation of phosphosites,
single-residue changes can have a more subtle,
indirect effect on phosphorylation-mediated processes.
The change in net charge in the spatial vicinity of a
phosphosite can alter the interaction mediated by the
PTM via electrostatic forces. To test the relevance of
this assumption in the case of germline DCMs, protein
structures were evaluated with regard to the typical
distance between phosphosites and DCMs/PMs that
change a neutral amino acid to a charged one. Figure 5
shows that the enrichment of charge-altering various
mutations has distinct distributions as a function of the
distance measured from the PTM site. Both positive
and negative charge-inducing DCMs are enriched inFig. 5. Enrichment of mutations inducing charge change in t
DCM).the spatial proximity of PTMs, indicating the relevance
of electrostatic modulation. This enrichment vanishes
as more distant residues are considered. Negative
DCMs seem to have a more long-range effect, with
residues even as far as 30–40 Å showing slight
enrichments.
Other types of PTMs can be crucially important in
functional regulation and signaling processes, with
more common ones, such as methylation or acety-
lation operating through charge as well. These could
serve as other possible points of modulation for
DCMs, and their analysis would be highly interest-
ing. Unfortunately, current low-throughput data on
these modifications is scarce and does not yet
enable the systematic analysis of their associations
with disease-linked mutations.Discussion
There are a handful of studies investigating structural
aspects ofmutations. These papersmostly analyze the
presence of disorder, effect of PTMs or the contribution
of surfaces to DCMs; however, the different properties
are investigated mostly independently. Machine learn-
ing is a great and often used [29–34] tool considering
interdependence of such features; it rather works like a
black-box machine, and therefore, it is hard to place
these features into proper biophysical context without a
complex analysis. In this manuscript, we attempt
to find unrevealed interrelationships between basiche environment of phosphorylated residues (blue, PM; red,
4964 Disease-Causing Germline Mutationscharacteristics. Besides statistical analysis, several
pieces of evidence come from detailed structure–
function studies of individual proteins.
The amount of germline SNVs and our structural
knowledge of the human proteome currently provide
the basis for the foundation of large-scale studies
concerning the relationship between genetic muta-
tions and protein structure. Our presented work is the
first of such works that utilizes the wealth of structural
knowledge of human proteins complemented with
high-quality TM and disorder predictors available that
enable the extension of our analysis to cover the
whole human proteome. The usage of state-of-the-art
predictors is of utmost importance, as nearly half of
human protein-coding genes contain long (N30 amino
acid) disordered regions [35], while structure determi-
nation of TMPs lags far behind of globular ones, those
would largely escape analysis considering experi-
mental data alone.
The power of our approach is apparent in its ability
to uncover large-scale systematic trends. These
trends clearly show that disease-causing germline
mutations (DCMs) are fairly similar to known somatic
cancer mutations in many ways. DCMs show a very
clear preference for structured protein parts with a
pronounced decrease on intrinsically disordered
protein regions (IDRs). IDRs are known to be more
tolerant against mutations due to the lack of structure
that could be disrupted via SNVs. From a phenotypic
viewpoint, this would make them ideal candidates for
DCMs as mutations in IDRs would potentially lead to
weaker phenotype changes, more compatible with
the ubiquitous presence of DCMs in all cells.
Surprisingly, DCMs seem to not utilize this effect,
similarly to cancer mutations [36]. In contrast, DCMs
do preferentially target TM regions—a distinct
difference compared to somatic cancer mutations.
This indicates that while cancer arises primarily as a
modulation of regulatory and signaling mechanisms
(often manifesting in altered transcription), germline
DCMs are more focused on the perturbation of
transport mechanisms across membranes.
While the general TM and globular prevalence of
DCMs is clear from the above analyses, mutations
belonging to given illnesses can show the possible
interplay of various structural variations. Considering
the structural distribution of DCMs, diseases can be
clearly split into various classes. These show thatwhile
a large number of conditions have a definite ordered-
protein background, in other cases disordered and TM
mutations play a heavy role in disease development,
and these mutations show interesting coordination
patterns. One large class utilizes a fairly high number
of disorderedmutations, inmany cases (such asRETT
syndrome; see Fig. 2) complementing variations in
ordered domains of the same protein. An alternative
molecular approach is presented by diseases mainly
focused on themodulation of TM protein regions (such
as ceroid lipofuscinosis)—in these cases, the interplayis between TM and ordered domains in the same
protein. This shows that illnesses characterized by
very different symptoms can share a very similar
molecular background, and hence, their therapeutic
optionsmay bemore similar than expected. In order for
structural analyses to have any therapeutic relevance,
they must be able to uncover specific molecular ways
of alteration that provide a mechanistic understanding
of the disease emergence. In accord, we analyzed
howDCMs target ordered, disordered andTM regions.
The most germline mutation-sensitive structural
regions belong to TM proteins, but this sensitivity is
highly dependent of the topology. The highest vulner-
ability is shown by the membrane-embedded parts of
polytopic TMPs. DCMs in this region manifest in the
disruption of helix packing either by disrupting weak
interactions or by strengthening helix–helix interactions
[37]. A prime example of this mechanisms is shown by
the thyrotropin receptor, a member of G-protein
coupled receptor family that stimulates thyroxine (T4)
and triiodothyronine production. Mutation of Val509 in
the third TM helix was shown to disrupt the van der
Waals packing between the third and fifth TM helices
[38,39]. In contrast, theV232Dmutation in themiddle of
the fourth TM segment of cystic fibrosis transmem-
brane conductance regulator (CFTR) introduces a
nonnative hydrogen bond with Q207 of the third TM
segment, perturbing the dynamics of the wild-type
protein by locking thehelices [40]. A second, alternative
mechanism is offered by the charge perturbation on
membrane proximal parts of polytopic TMPs, especial-
ly on the cytosolic side close to positively charged
residues. According to the positive-inside rule, posi-
tively charged amino acids are more frequent on the
cytosolic side near to the membrane [41,42]. It is
plausible that variations occurring around this region
can prevent the proper folding of TMPs by effectively
modulating their orientation via perturbed interaction
with the negatively charged glutamate in the cytosolic
segment of the translocon, the negatively charged
phospholipids on the cytosolic side and the electro-
chemical membrane potential. These membrane
proximal regions are typically highly dynamic and
constitute a special class of IDPs [43].While disordered
residues in general are tolerant to variations, these
flexible segments are mutation sensitive owing to the
fact that they may aid the stabilization of the protein by
interacting with lipid head groups.
The vast majority of DCMs in membrane proximal
loops alter the transport activity if either positively
charged [44,45] or other residues [46,47] are altered,
as they are in direct proximity of material transport. A
well-characterized such example is TRPV4, a non-
selective osmotic and mechano-sensitive cation
channel. Different mutations near a functionally
important charged residue next to the cytosol-
membrane boundary boost protein activity by twisting
the backbone and increasing the open probability of
the channel [48,49] leading to an increased
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development (spondylometaphyseal dysplasia
Kozlowski disorder). Other known diseases related
to signaling [50,51] or energy production [52] also
connected to this region, albeit emerging with a lower
frequency.
DCMs targeting ordered and disordered proteins
provide molecular mechanisms complementary to
the so-far discussed TMP mutations. Similarly to
known somatic mutations, germline DCMs also
preferentially target either the buried core of domains
or—in the case of interacting proteins—PPI inter-
faces. Buried and interface parts have important role
to keep up the structural integrity of proteins or
protein complexes. For instance, mutations in
ABCC6 are responsible for pseudoxanthoma elas-
ticum, a progressive disorder causing the accumu-
lation of deposits of calcium. It was shown that
mutations causing pseudoxanthoma elasticum tend
to cluster in the domain–domain interface of the
complex, where they can disrupt the proper behavior
of the protein [8]. Energetic analysis of such DCMs
shows that the main effect of these mutations is the
destabilization of ordered monomeric or oligomeric
protein structures. Surprisingly, calculated energetic
changes are highly destabilizing, with average ΔΔG
contributions surpassing 2 kcal/mol for single-resi-
due changes. This shows that the weaker pheno-
typic changes of germline mutations compared to
that of somatic variations are not a reduced ΔΔG
change but rather the choice of target proteins. An
interesting example is provided by the A → V
mutation in the leucine-rich repeat in platelet
glycoprotein Ib, responsible for Bernard–Soulier
syndrome. On one hand, the mutation results in a
conformational change that affects the interaction
with the membrane. On the other hand, the same
mutation decreases the affinity of binding between
the protein and the von Willebrand factor, most likely
by altering the orientation of negatively charged
residues playing a key role in the interaction [53].
In the case of IDPs, such energetic calculations
based on structure are not generally feasible. Howev-
er, IDPs bound to protein partners generally adopt
stable conformations that can lend themselves to
analyses similar to that of ordered interactions. The
studied IDPcomplexes show that the twomechanisms
available for ordered interacting proteins (i.e., stability
changes via buried or interface residues) narrow down
to a single option of modulating the interaction strength
via DCMs. IDPs binding to ordered partners generally
adopt an extended conformation, usually devoid of
buried residues. Protein complexes formedexclusively
by IDPs, however, have a larger fraction of buried
residues, and in theory, this could provide an option for
destabilization of the oligomeric structure. Still, our
results show that this option is basically never used in
known examples, and even IDP-only complexes are
targeted solely via interface destabilization. Interest-ingly, in IDP-mediated interactions, the energetic
contributions of germline DCMs surpass the contribu-
tion of DCMs in ordered structures, providing a more
pronounced destabilizing effect. As IDPs tend to
mediate weaker interactions, this comparatively larger
energetic effect possibly results in a larger increase in
Kd values, promoting a more intensive dissociation, as
exemplified by acetylcholinesterase, which is a protein
complex formed by various subunits forming a
tetramer coiled coil upon oligomerization. Missense
mutations in the proline-rich attachment domain are
responsible for myasthenic syndrome by preventing
the formation of the protein assembly, leading to
fatigability and muscle weakness [54].
Such weakened structures and interactions can
highlight mutations with serious molecular effect
providing insights into how the disease forms.
However, while such energetic studies are useful,
caution should be exercised when interpreting them,
as other cellular processes can modulate structural
effects. For example, one of the mutations with the
highest destabilizing effect occurs in the Polycomb
complex protein BMI-1, a protein playing role in
neural stem cell self-renewal [55]. C18Y is a PM that
disrupts the RING finger helping zinc coordination
[56]; however, the calculated ΔΔG value is ~39 kcal/
mol, seemingly incompatible with a neutral pheno-
typic change. The calculated destabilization indeed
does happen; however, the protein unfolds and gets
degraded. Mouse studies have shown that as long
as the healthy protein gets synthesized from a
different allele, the total change in fitness is only
marginal compared to healthy ones, and symptoms
are negligible compared to Bmi1−/− mutants [57].
In the mechanisms discussed so far, the affected
protein unit was a domain, a TM segment or a
disordered binding region, all comprising several
residues. Apart from these functional units, a large
proportion of proteins feature single-residue functional
units as well in the form of PTM sites. According to
estimates, the human proteome features over a million
PTM sites providing prime targets for disease-
associated SNVs [58]. As each type of PTMs requires
a specific residue in order to occur (e.g., S/T or Y for
phosphorylation), mutations can easily disrupt signal-
ing and regulatory events by changing the residue. This
would provide a complementary mechanism of regu-
latory modulation in addition to the previously dis-
cussed structural modulation mechanisms. While
PTMs are often modulated via somatic cancer muta-
tions, either as removal of the possibility of a PTM or as
the introduction of a phosphomimetic residue [59–61],
this mechanisms is largely missing in the case of
germline DCMs. Phosphomimetic germline mutations
are virtually non-existent, and PTM abolishing muta-
tions are also rare. The disease that shows the highest
overlap between known DCMs and PTM sites is the
von Hippel Lindau syndrome, which is a cancer-
disposition syndrome. In this case, DCMs remove
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however, the actual emergence of the disease state
(renal clear cell carcinoma) requires additional somatic
mutations to occur [62]. Furthermore, a large fraction of
germline VHL mutations coincide with known somatic
mutations, showing that VHL represents the borderline
between germline and somatic disease mechanisms.
This shows that direct PTM modulation predominantly
belongs to the realm of somatic mutations with strong
phenotype.
Apart from the direct modulation of PTMs, these
sites are readily modifiable via less drastic changes
as well. Phosphorylation introduces a negative
charge to the protein; therefore, it can be assumed
that charge deviance near phosphorylation sites can
also have serious consequences. Compared to the
direct mutation, a weaker effect can be observed by
increasing net charge in proximity to the site. For
example, the G121R variation in phosphoglucomu-
tase-1 near to the phosphothreonine at position 115
reduces the catalytic activity of the protein, probably
by altering the conformation of the phosphorylation
site, as proposed by Lee et al. [63].
These results emphasize that, to our current
knowledge, the primary effect of germline DCMs is
the modulation of structural features of proteins and
protein complexes. This means that structural
information alone without knowledge of regulatory/
pathway information of a given site of a protein
should largely be enough to determine the detrimen-
tal nature of occurring mutations. Structural consid-
erations in the interpretation of disease-associated
mutations with weak phenotypes provide the major
clues to the understanding of how these diseases
develop. Comprehensive studies based on large-
scale data can provide this knowledge and can be
further utilized to offer better diagnostics.Methods
Data sets
Humangenetic variation data (PMs andDCMs) were
obtained from the UniProt database (version 2017_07)
(http://www.uniprot.org/docs/humsavar) [64]. Se-
quences in the human proteome were filtered to 40%
identity withCD-HIT [65], andmutationswere kept from
only one sequence of each redundancy cluster. After
redundancy filtering, 28,499 PMs and 20,608 DCMs
remained.
The PDB database [66] was filtered, and only X-ray
structureswith a resolution better than 3.5 Åwere kept.
Chimeric proteins were discarded. PDB entries were
only kept if nearly all residues have structural informa-
tion (at least 90% of side-chain atoms are present) or it
was completelymissing (side-chain atoms aremissing,
corresponding to disordered/highly flexible residues)—the latter cases provided a subset of disordered
proteins. In addition, single-subunit and oligomeric
structures were separated into two groups.
Protein complexes formed through autonomous
folding and independent binding, coupled folding and
binding, and mutual synergistic folding were selected
the same way as described by Mészáros et al. [18]
based on the DIBS [67] and MFIB [68] databases.
These data sets already employ a consistent level of
similarity filtering, thus no further redundancy filtering
was performed.
Both PMs and DCMs were mapped to structures
from the PDB. This was done using BLAST search
on the redundancy filtered human proteome against
sequences in the filtered PDB with a 10−10 e-value
cutoff. Hits above 40% identity were further proc-
essed by a greedy algorithm to select the least
structures to which the most mutations can be
mapped to. This step was performed for both
single-subunit and oligomeric structures. A total of
3916 PMs and 8103 DCMs were mapped onto 1532
oligomeric protein structures, and 2654 PMs and
5217 DCMs were mapped onto 1075 single-subunit
proteins. Assigning mutations to proteins where the
folding and binding mode could be recognized
resulted in 576 structures where 223 PMs and 464
DCMs were identified. On TMPs, 8276 PMs and
7055 DCMs were detected.
Classifying residues as ordered, disordered and
TM
Residues containing PMs and DCMs were classi-
fied into three classes (TM, disordered or ordered)
using two different approaches. In the first one,
residues in the membrane regions of TMPs were
determined using HTP d1.4 [69,70]. Disordered and
ordered residues were defined based on DisProt [71],
PFAM [72] and IUPred [73,74] by the following rules:
Residues of knownPfamdomains were considered to
be ordered. Residues outside such domains were
considered disordered if they were annotated as such
in DisProt or if were predicted to be disordered by
IUPred using the standard “long” setting. In the case of
TMPs, IUPred was run with the “short” setting, as we
found that its accuracy is higher for TMPs [75].
To ensure disorder definition is not biased by the
prediction, disordered residues were also assigned
using three approaches with different stringency and
scope, using structural information as well: (I) using
only DisProt annotations, (II) considering only residues
with missing side-chain atoms in PDB structures, and
(III) considering all proteins for which no structural
assignment could be done (non-TMP and no available
X-ray structure). While the third category obviously
contains non-disordered residues aswell, it is expected
to be enriched in segments with no stable structure and
can be useful when being contrasted with results from
strictly structured sets.
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were classified as bitopic and polytopic proteins
depending of the number of membrane-spanning
segments. Connecting loops between TM helices
were divided into “outside membrane proximal”
[extra-cytosolic, max 5 amino acid (AA) from
membrane boundary]; “outside loop” (extra-cytosol-
ic, at least 6 AA from membrane boundary); “inside
membrane proximal, near charged” [cytosolic, max 5
AA from membrane boundary with a positively
charged (Arg, Lys) residue within the 5AA]; “inside
membrane proximal, far from charged” [cytosolic,
max 5 AA from membrane boundary without a
positively charged (Arg, Lys) residue within the
5AA]; and “inside loop” (cytosolic, at least 6 AA
from membrane boundary).
Hierarchical clustering
Hierarchical clustering was done using the hclust
package in R, using Ward's method [76] (ward.D2)
and euclidean distances. K-means clustering was
performed using the kmeans package in R.
Functional analysis
PANTHER Overrepresentation Test (Release
20,171,205) was performed using PANTHER ver-
sion 13.0 (release 2017-11-12) using PANTHER GO
Slim—biological processes [77].
Residue classifications based on structure
Solvent accessible surface area (SASA) is calcu-
lated as described by Lee and Richards [78].
Residues belonging to protein–protein complex
interfaces were defined by assessing the SASA
values for each subunit in the bound form and by
removing all other partner chains in the complex. For
interface residues, the SASA values in the two
configurations are different. All other residues were
classified into buried (up to 9% of maximum
accessible surface was calculated in the structure)
or exposed (at least 36% of maximum accessible
surface was present) [79]. Residues for which side-
chain atoms were missing in constitutive 5 amino
acids were classified as disordered. DSSP [80] was
run on all structures, and residues were classified
into four groups: helix (“H,” “G” and “I” output),
extended (“B” and “E”), turn/bend (“S” and “T”) and
irregular (“-“). Only standard amino acids were
considered.
Energy calculations
Energy calculations were performed using FoldX
[81]. Only mutations where the assigned structure
and the original protein had 100% sequence identity
were considered. ΔΔG calculations were executedon previously optimized structures and were per-
formed five times. All reported ΔΔG values represent
the average of these independent runs.
PTMs
Phosphorylation, methylation and acetylation data
were collected from PhosphoELM [82], UniProt [64]
and PhosphoSitePlus [83] using only low-throughput
experiments.
Statistical analysis
χ2 Tests were performedonall datawhere indicated.
In case of low values (below 5 for any category), Fisher
exact test was used. To further eliminate the sporadic
error of the data and to estimate the standard
deviations, bootstrap analysis was performed by
randomly selecting 80% of the data 100 times.
Numbers of occurrences were collected in contin-
gency tables to serve as input for statistical analyses
(see Supplementary Material and Supplementary
Table 1):Mutation (PM or DCM) No mutationNot in structural part x1 x2
In structural part x3 x4The enrichment of one kind of mutation in a certain
structural part is the relative frequency of a variation
in a given structural part divided by the relative
frequency of residues in the given structural part in
all residues:





x1þx2þx3þx4:DCM PMNot in structural part d1 p1
In structural part d2 p2Odds ratio was calculated as described Gao et al.
[12]: d2=p2d1=p1
Kolmogorov–Smirnov tests were performed to
compare samples whether they have the same
distribution.Funding
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